Quantifying the Age of Evidence: Lessons From Cardiovascular Drugs
Journal of Evaluation in Clinical Practice · 2026-03 · 32 (2)
DOI: 10.1111/jep.70412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Evaluation in Clinical Practice, online erschienen am 19.03.2026. Verfasst von Mariana B Caiado Ferreira und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medicine 1, Unidade Local de Saúde São José, Lisbon, Portugal. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Sodium-Glucose Transporter 2 Inhibitors, Evidence-Based Medicine. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Arnold Ventures.
Abstract (Originalsprache)
Background
All evidence‐based medical decisions rely on the assumption that the evidence being used is applicable to current populations. To date, the age of evidence is not typically measured nor reported in systematic reviews.
Methods
We sought to develop a method to quantify the age of evidence for medical interventions, using statins and sodium‐glucose co‐transporter protein 2 (SGLT‐2) inhibitors as exemplars, which may facilitate evaluating its potential outdatedness. We conducted a retrospective cross‐sectional study of all Cochrane reviews evaluating the effects of these drugs on cardiovascular disease (CVD) management up to August 2024, summarising the evidence and calculating the lag in time between patient enrolment in trials and current decision‐making (August 2024).
Results
We identified 57 Cochrane reviews on statins, with 9 (15.8%) meeting our criteria, and 6 reviews on SGLT‐2 inhibitors, with 2 (33.3%) being eligible. The 9 statin reviews include 153 different trials, enrolling participants from 1988 to 2017, spanning 28 years. The 2 SGLT‐2 inhibitor reviews involve 67 trials from 2008 to 2021, spanning 13 years. The median age of evidence for statins is 24.1 years, compared to 8.6 years for SGLT‐2 inhibitors. Among the statin review topics, evidence was most robust for statins in the context of primary prevention of CVD.
Conclusions
Our findings highlight the potential outdatedness of long‐established treatments like statins and suggest that reporting the age of evidence in systematic reviews may facilitate outdatedness assessments. We propose that future Cochrane reviews report the age of evidence, as this could significantly enhance the decision‐making process in evidence‐based medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicine 1, Unidade Local de Saúde São José, Lisbon, Portugal.
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
ORCID-Profile: Mariana B Caiado Ferreira
Förderung
- Arnold Ventures
Zitieren
APA
Ferreira, M. B. C., & Prasad, V. (2026). Quantifying the Age of Evidence: Lessons From Cardiovascular Drugs. Journal of Evaluation in Clinical Practice, 32(2). https://doi.org/10.1111/jep.70412
Vancouver
Ferreira MBC, Prasad V. Quantifying the Age of Evidence: Lessons From Cardiovascular Drugs. Journal of Evaluation in Clinical Practice. 2026;32(2). doi:10.1111/jep.70412
BibTeX
@article{Ferreira2026,
author = {Ferreira, Mariana B Caiado and Prasad, Vinay},
title = {Quantifying the Age of Evidence: Lessons From Cardiovascular Drugs},
journal = {Journal of Evaluation in Clinical Practice},
year = {2026},
volume = {32},
number = {2},
doi = {10.1111/jep.70412}
}
EUVIMED